CCM
REGN icon

Catalio Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Catalio Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-29,797
Closed -$23M – 50
2025
Q4 		$23M Sell
29,797
-5,547
-16% -$3.77M 4.07% 10
2025
Q3 		$19.9M Buy
+35,344
New +$20M 3.67% 12
2025
Q2 		– Sell
-12,261
Closed -$7.78M – 46
2025
Q1 		$7.78M Buy
+12,261
New +$8.43M 1.89% 17

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Catalio Capital Management's REGN Position: Q1 2026 in Review

Catalio Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 29,797 shares — an estimated $23M sold.

Catalio Capital Management first reported a position in REGN in Q1 2025 and held it in 3 quarters. The position peaked at $23M in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Catalio Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Catalio Capital Management sold 29,797 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $23M.
  • Catalio Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2025 and held it in 3 quarters.
  • Catalio Capital Management's Regeneron Pharmaceuticals position peaked at $23M in Q4 2025.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Catalio Capital Management's 13F filing for Q1 2026, filed 15 May 2026.